Radiation pneumonitis in lung cancer patients: A retrospective study of risk factors and the long-term prognosis

被引:146
作者
Inoue, A
Kunitoh, H
Sekine, I
Sumi, M
Tokuuye, K
Saijo, N
机构
[1] Natl Canc Ctr, Dept Med Oncol, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Div Radiat Oncol, Chuo Ku, Tokyo 1040045, Japan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2001年 / 49卷 / 03期
关键词
lung cancer; radiation pneumonitis; risk factor; prognosis; corticosteroid;
D O I
10.1016/S0360-3016(00)00783-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To retrospectively evaluate the risk factors for acute radiation pneumonitis (RP) and long-term prognosis of patients with lung cancer treated by thoracic radiotherapy. Methods and Materials: Of the 256 lung cancer patients who underwent definitive thoracic radiotherapy between June 1988 and May 1998, the 191 patients who were capable of being evaluated were divided into three groups according to the grade of RP, RP was defined as "severe," when it caused severe clinical symptoms, such as intractable cough, dyspnea at rest, and the need for oxygen or steroid therapy. The definition was made by using a modification of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer acute radiation morbidity scoring criteria. Factors that influenced the incidence of severe RP were assessed by using the Mantel-Haenszel chi (2) test in the univariate analysis and the logistic regression test in the multivariate analysis. Survival rates was calculated by using the Kaplan-Meier method, and the p values indicating the significance of differences between the RP groups were calculated by the log-rank test. Results: Of the 94 patients (49%) who experienced clinical RP in this study, the RP was mild in 69 (36%) and severe in 25 (13%) patients. The 3-year survival rates of the patients who experienced no, mild, and severe RP were 33.4%, 38.2%, and and 0%, respectively, and the survival rate of the patients who experienced severe RP was significantly poorer than the other two groups combined (p = 0.0028). The incidence of severe RP did not correlate with any of the baseline patient characteristics, radiotherapeutic factors, or chemotherapeutic variables. Two clinical risk factors were identified from medical records before radiotherapy: low PaO2 (< 80 torr) and high C-reactive protein (CRP) (> 1.0 ng/mL), Both of them were significantly related to the development of severe RP in the univariate analysis (p = 0.004 and 0.013, respectively), and low PaO2 remained a significant risk factor in the multivariate analysis (p = 0.034). Multivariate analysis also revealed the occurrence of severe RP to be the most important factor determining poor survival (p = 0.0065). There was no significant difference in survival rate according to whether the patients had been treated with corticosteroids, Conclusion: Mild and severe RP occurred in 69 (36%) and 25 (13%), respectively, of 191 lung cancer patients who had undergone irradiation of the chest. Only severe RP was an adverse prognostic factor. Low PaO2 (< 80 torr) before radiotherapy was a significant risk factor predictive of severe RP, The role of corticosteroids in RP could not be accurately determined. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 24 条
[1]   CHANGES IN PLASMA TGF-BETA LEVELS DURING PULMONARY RADIOTHERAPY AS A PREDICTOR OF THE RISK OF DEVELOPING RADIATION PNEUMONITIS [J].
ANSCHER, MS ;
MURASE, T ;
PRESCOTT, DM ;
MARKS, LB ;
REISENBICHLER, H ;
BENTEL, GC ;
SPENCER, D ;
SHEROUSE, G ;
JIRTLE, RL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (03) :671-676
[2]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[3]   Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial [J].
Dillman, RO ;
Herndon, J ;
Seagren, SL ;
Eaton, WL ;
Green, MR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1210-1215
[4]   A RANDOMIZED TRIAL OF INDUCTION CHEMOTHERAPY PLUS HIGH-DOSE RADIATION VERSUS RADIATION ALONE IN STAGE-III NON-SMALL-CELL LUNG-CANCER [J].
DILLMAN, RO ;
SEAGREN, SL ;
PROPERT, KJ ;
GUERRA, J ;
EATON, WL ;
PERRY, MC ;
CAREY, RW ;
FREI, EF ;
GREEN, MR .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :940-945
[5]   TREATMENT OF LIMITED-STAGE SMALL-CELL LUNG-CANCER WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND VINCRISTINE WITH OR WITHOUT ETOPOSIDE - A RANDOMIZED TRIAL OF THE NORTH-CENTRAL-CANCER-TREATMENT-GROUP [J].
JETT, JR ;
EVERSON, L ;
THERNEAU, TM ;
KROOK, JE ;
DALTON, RJ ;
MARSCHKE, RF ;
VEEDER, MH ;
BRUNK, SF ;
MAILLIARD, JA ;
TWITO, DI ;
EARLE, JD ;
ANDERSON, RT .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :33-38
[6]   MULTIMODAL THERAPY FOR LIMITED SMALL-CELL LUNG-CANCER - A RANDOMIZED STUDY OF INDUCTION COMBINATION CHEMOTHERAPY WITH OR WITHOUT THORACIC RADIATION IN COMPLETE RESPONDERS - AND WITH WIDE-FIELD VERSUS REDUCED-FIELD RADIATION IN PARTIAL RESPONDERS - A SOUTHWEST ONCOLOGY GROUP-STUDYA [J].
KIES, MS ;
MIRA, JG ;
CROWLEY, JJ ;
CHEN, TT ;
PAZDUR, R ;
GROZEA, PN ;
RIVKIN, SE ;
COLTMAN, CA ;
WARD, JH ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (04) :592-600
[7]   Cancer statistics, 1998 [J].
Landis, SH ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1998, 48 (01) :6-+
[8]   QUANTITATIVE EFFECT OF COMBINED CHEMOTHERAPY AND FRACTIONATED RADIOTHERAPY ON THE INCIDENCE OF RADIATION-INDUCED LUNG DAMAGE - A PROSPECTIVE CLINICAL-STUDY [J].
MAH, K ;
KEANE, TJ ;
VANDYK, J ;
BRABAN, LE ;
POON, PY ;
HAO, Y .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (03) :563-574
[9]   CONCURRENT CHEMOTHERAPY - RADIOTHERAPY FOR LIMITED SMALL-CELL LUNG-CARCINOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY [J].
MCCRACKEN, JD ;
JANAKI, LM ;
CROWLEY, JJ ;
TAYLOR, SA ;
GIRI, PGS ;
WEISS, GB ;
GORDON, W ;
BAKER, LH ;
MANSOURI, A ;
KUEBLER, JP .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) :892-898
[10]   INJURY TO THE LUNG FROM CANCER-THERAPY - CLINICAL SYNDROMES, MEASURABLE END-POINTS, AND POTENTIAL SCORING SYSTEMS [J].
MCDONALD, S ;
RUBIN, P ;
PHILLIPS, TL ;
MARKS, LB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1187-1203